Markets:

Overview

News

Currencies

International

Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.329 +0.019 (+1.45%)

Streaming Delayed Price Updated: 10:06 AM EDT, Jul 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

August 04, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Two Biotech Stocks Poised For Big Moves On Monday ↗

June 23, 2025

Via Benzinga

Beyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics Stock ↗

March 11, 2025

Via Benzinga

Forecasting The Future: 6 Analyst Projections For Lineage Cell Therapeutics ↗

January 31, 2025

Via Benzinga

The Analyst Verdict: Lineage Cell Therapeutics In The Eyes Of 4 Experts ↗

January 03, 2025

Via Benzinga

OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025

June 23, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium

June 05, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 14, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Examining the Future: Lineage Cell Therapeutics's Earnings Outlook ↗

May 12, 2025

Via Benzinga

Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

May 01, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Earnings Scheduled For May 13, 2025 ↗

May 13, 2025

Via Benzinga

RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025

May 12, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

April 22, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Which stocks are moving after the closing bell on Wednesday? ↗

April 16, 2025

Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

April 21, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 16, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

April 15, 2025

Via Benzinga

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 10, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Earnings Scheduled For March 10, 2025 ↗

March 10, 2025

Via Benzinga

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

March 05, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference

February 04, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury

February 11, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

January 27, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Issues Letter to Stockholders

January 06, 2025

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

November 21, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 20, 2024

Via Benzinga

Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

November 20, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 14, 2024

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Earnings Scheduled For November 14, 2024 ↗

November 14, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

All News about Lineage Cell Therapeutics, Inc. Common Stock

Starting at $3.75/week.

Subscribe Today